Our Story
Ksilink runs a one-of-a-kind phenotypic drug discovery engine with an emerging proprietary pipeline of patient-based CNS programs.
What we do
Through our patient-based phenotypic approach and a robust network of academic, clinical, and patient stakeholders, we are driving innovation in patient-based science to unlock high-value opportunities in markets with significant unmet medical needs.
Our business model
Building on our proven track record in muscular diseases, we are now advancing proprietary CNS programs toward preclinical candidates and beyond. Our drug discovery engine, designed as a unique, disease-agnostic platform to foster patient-based innovation, is open to strategic partners across all therapeutic areas.
Our differentiating features
Ksilink has a worldwide unique capacity to automate complex patient-based disease models for drug discovery. Our AI-powered morphometric read-outs of multiple cellular features and capacity to enter into high-throughput phenotypic screening sets us appart. Our automated human cellular systems are supporting preclinical drug discovery with a strong in vitro human proof of concept.
Our why
Through robust in vitro human science, we aim to significantly reduce late-stage failure rates caused by poorly understood diseases, incorrect target selection, and inadequate in vivo models.
LAUNCH
Derisking innovation with public funding as Ksilink Association
The project is launched and set up, thanks to strong impulse from Inserm and Sanofi, and 16m€ funding from French Programme d’Investissement d’Avenir (PIA) to initiate programs for academia and biotech.
ACCELERATION
Moving Ksilink to the next step
Ksilink recruits own staff and invest into a tailored fully-automated sterile screening platform.
EXPLOITATION
Incorporation of Ksilink SAS
The technology platform and the team are transferred to a spin-off in the form of a limited company (SAS) to exploit its technical expertise and drive a proprietary pipeline up to valuable endpoints for the industry.
